Android app on Google Play

Arena Pharmaceuticals (ARNA) Must Conduct 6 Post-Marketing Studies

June 27, 2012 1:00 PM EDT Send to a Friend
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) must conduct 6 post-marketing studies for diet pill lorcaserin.

With Arena still halted, traders will be watching VIVUS Inc. (Nasdaq: VVUS), Orexigen (Nasdaq: OREX).




You May Also Be Interested In


Related Categories

FDA, Momentum Movers, Trader Talk

Add Your Comment